{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T16:40:11Z","timestamp":1717519211076},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Associazione Italiana Contro le Leucemie-Linfomi e Mieloma ONLUS."}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.blre.2014.10.001","type":"journal-article","created":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T12:40:16Z","timestamp":1414845616000},"page":"143-152","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma"],"prefix":"10.1016","volume":"29","author":[{"given":"Alberto","family":"Mussetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parastoo B.","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2014.10.001_bb0005","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0010","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0015","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2014.10.001_bb0030","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2014.10.001_bb0035","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0040","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2014.10.001_bb0045","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0050","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0055","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0060","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2014.10.001_bb0065","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0070","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for blood and marrow transplantation","volume":"16","author":"Cook","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2014.10.001_bb0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2040620710396752","article-title":"Long-term results of fludarabine\/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: the GELTAMO experience","volume":"2","author":"Gayoso","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2014.10.001_bb0080","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/annonc\/mds054","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed\/refractory mantle cell lymphoma: a multicenter experience","volume":"23","author":"Le Gouill","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0085","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2014.10.001_bb0090","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0095","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","article-title":"Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"25","author":"Dietrich","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/1096-8652(200009)65:1<75::AID-AJH14>3.0.CO;2-L","article-title":"Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL","volume":"65","author":"Sohn","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2014.10.001_bb0105","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2014.10.001_bb0110","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1705074","article-title":"Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation","volume":"36","author":"Russell","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2014.10.001_bb0115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbmt.2007.04.013","article-title":"High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma","volume":"14","author":"Bloor","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2014.10.001_bb0120","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.bbmt.2011.03.010","article-title":"Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation","volume":"17","author":"Ram","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2014.10.001_bb0125","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Belch","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0135","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0140","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0145","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1535-7163.MCT-10-1108","article-title":"Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo","volume":"10","author":"Dasmahapatra","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2014.10.001_bb0150","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdu142","article-title":"Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma","volume":"25","author":"Gill","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0155","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0400","series-title":"ASH 2013 Abstract #1789","article-title":"The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients","author":"Davids","year":"2013"},{"key":"10.1016\/j.blre.2014.10.001_bb0165","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0170","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1080\/10428190701618268","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma","volume":"48","author":"Rodr\u00edguez","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2014.10.001_bb0175","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/10428190801993470","article-title":"Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group","volume":"49","author":"Witzig","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2014.10.001_bb0180","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0185","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0190","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2014.10.001_bb0195","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0200","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0205","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0210","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/10428194.2010.546015","article-title":"A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)","volume":"52","author":"Kouroukis","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2014.10.001_bb0215","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0220","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2014.10.001_bb0225","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0230","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0235","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","article-title":"Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study","volume":"24","author":"Zinzani","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0240","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.blre.2014.10.001_bb0245","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2014.10.001_bb0250","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0255","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0260","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/cncr.21313","article-title":"Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"104","author":"Thieblemont","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2014.10.001_bb0265","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-006-0193-2","article-title":"The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma","volume":"86","author":"Ritchie","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2014.10.001_bb0270","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2011-07-369629","article-title":"Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL database","volume":"119","author":"Lacasce","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0275","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0280","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","article-title":"High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission","volume":"16","author":"Freedman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0285","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1080\/10428190801923725","article-title":"Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma","volume":"49","author":"Till","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2014.10.001_bb0290","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0295","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0405","series-title":"An Analysis from the Lymphoma Working Party of the EBMT ASH 2008 abstract #457","article-title":"Identification of prognostic factors predicting the outcome of reduced intensity allogeneic stem cell transplantation in mantle cell lymphoma","author":"Robinson","year":"2008"},{"key":"10.1016\/j.blre.2014.10.001_bb0410","series-title":"ASH 2013 Abstract #3405","article-title":"The EBMT lymphoma working party-European mantle cell lymphoma network consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma: recommendations applying the Delphi procedure","author":"Robinson","year":"2013"},{"key":"10.1016\/j.blre.2014.10.001_bb0310","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1008380527502","article-title":"Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy","volume":"10","author":"Khouri","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0315","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1083-8791(01)70016-X","article-title":"Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma","volume":"7","author":"Berdeja","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2014.10.001_bb0320","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/10428190400015022","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma \u2014 does it deserve a better look?","volume":"46","author":"Rifkind","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2014.10.001_bb0325","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":"Hematopoietic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Ganti","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0330","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ajh.20646","article-title":"Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma","volume":"81","author":"Laudi","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2014.10.001_bb0335","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbmt.2004.09.007","article-title":"Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma","volume":"11","author":"Kasamon","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2014.10.001_bb0340","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","article-title":"Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma","volume":"12","author":"Rodriguez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2014.10.001_bb0345","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.bbmt.2009.01.010","article-title":"Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas","volume":"15","author":"Hamadani","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2014.10.001_bb0350","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.10.001_bb0415","series-title":"ASH 2013 Abstract #2093","article-title":"Association of graft vs. host disease (GVHD) with a lower relapse\/progression rate after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning in patients with follicular and mantle cell lymphoma: a CIBMTR analysis","author":"Urbano-Ispizua","year":"2013"},{"key":"10.1016\/j.blre.2014.10.001_bb0360","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/sj.bmt.1701540","article-title":"Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma","volume":"23","author":"Grigg","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2014.10.001_bb0365","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.bbmt.2011.02.009","article-title":"Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome","volume":"17","author":"Wudhikarn","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2014.10.001_bb0420","series-title":"ASH 2012 Abstract #733","article-title":"Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index (HCT-CI) for HCT outcomes at US transplant centers: a center for international blood and marrow transplant research (CIBMTR) study","author":"Sorror","year":"2012"},{"key":"10.1016\/j.blre.2014.10.001_bb0375","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyper CVAD alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2014.10.001_bb0380","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0385","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine\u2013rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.10.001_bb0425","series-title":"ASH annual Meeting Abstracts. 2013 Abstract #4384","article-title":"Radioimmunotherapy in relapsed\/refractory mantle cell lymphoma patients: final results of a European MCL Network phase ii trial","author":"Ferrero","year":"2013"},{"key":"10.1016\/j.blre.2014.10.001_bb0395","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X14000836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X14000836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T16:19:21Z","timestamp":1717517961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X14000836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0268960X14000836"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2014.10.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2014.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}